You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Oregon Health & Science University
Headquarters:Portland, OR
Year Founded:1974
Status:Academic
Biopharma related deals can be found by searching the organization's name in the BCIQ Deals Module*.*desktop version only

BioCentury | Dec 13, 2016

Distillery Therapeutics

Hepatic

...email: leeseung@snu.ac.kr CONTACT: Jae W. Lee, Oregon Health and Science University, Portland, Ore. email: leejae@ohsu.edu Hongjiang Li Oregon Health &...

BioCentury | Apr 07, 2021

Distillery Therapeutics

Toxin-derived YBX1 inhibitor for ovarian cancer

...Chem. Biol.; published online March 12, 2021doi:10.1016/j.chembiol.2021.02.014CONTACT: Sanjay V. Malhotra, Stanford University School of Medicine, Palo Alto, Calif.; Oregon Health &...

BioCentury | Jul 17, 2020

Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

...Gilead, he said, was that Brian Druker, the director of the Knight Cancer Institute at Oregon Health &...

BioCentury | Jun 13, 2020

Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

...of liver metastases. Checkpoint inhibitors restore T cell function in AML A team led by Oregon Health &...
...Programmed cell death 1 TIM3 (HAVCR2) - T cell immunoglobulin and mucin domain 3 BioCentury Staff Oregon Health &...

BioCentury | Jun 10, 2020

Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...built on technology from co-founder Tom Scanlan, a professor of chemical physiology and biochemistry at Oregon Health &...
...San Diego, Calif. Technology: Small molecule THRB agonist and brain-targeting chemistry platform Origin of technology: Oregon Health &...

BioCentury | Jun 04, 2020

Product Development

WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial

...Data to Health is using part of a $25 million NIH award to support the Oregon Health &...

BioCentury | Nov 04, 2019

Dual TLR7 and TLR8 agonism for pancreatic cancer

...Oct. 15, 2019 doi:10.1038/s41467-019-12657-w CONTACT: Daniel L. Marks, Oregon Health & Science University, Portland, Ore. email: marksd@ohsu.edu Claire Quang Oregon Health &...

BioCentury | Aug 29, 2019

Distillery Therapeutics

Cytomegalovirus vectors could form the backbone of an HIV vaccine

...July 17, 2019 doi: 10.1126/scitranslmed.aaw2607 CONTACT: Louis J. Picker, Oregon Health & Science University, Ore. e-mail: pickerl@ohsu.edu Inhua Muijrers-Chen Oregon Health &...

BioCentury | Aug 29, 2019

Translation in Brief

Cytomegalovirus vectors for a prophylactic HIV vaccine

...exacerbation of HBV and risk of drug resistance when used as PrEP. A team from Oregon Health &...
...that the virus is arrested and cleared before establishment of a virus reservoir.” Louis Picker, Oregon Health &...
...has licensed the rights to OHSU’s CMV vaccine platform. Financial terms are undisclosed. Inhua Muijrers-Chen, Associate Editor Oregon Health &...

BioCentury | Aug 08, 2019

Distillery Techniques

Mouse model of autoimmune encephalitis for screening therapies

...July 10, 2019 doi:10.1126/scitranslmed.aaw0044 CONTACT: Gary L. Westbrook, Oregon Health & Science University, Portland, Ore. email: westbroo@ohsu.edu Claire Quang Oregon Health &...

BioCentury | Jun 14, 2019

Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...as SVP commercial. He was innovation, IP and commercialization manager at Knight Cancer Institute at Oregon Health &...

BioCentury | Jun 06, 2019

Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

...almost 80%. Zhang's new study comes just three days after Shoukhrat Mitalipov and colleagues at Oregon Health &...
...protein 9; RAD51 - RAD51 homolog Lauren Martz, Associate Editor Broad Institute of MIT and Harvard Editas Medicine Inc. Oregon Health &...

BioCentury | Jun 05, 2019

Finance

Conflicts over scale, response to foreign threats and espionage against NIH research at Senate hearing

...foreign-born scientists.” “We run the risk of stifling innovation whenever we constrain interactions.” Joe Gray, Oregon Health &...
...is as bone-headed as it gets.” Joe Gray, associate director for biophysical oncology at the Oregon Health &...
...there was evidence the researcher was engaged in “some nefarious activity.” Companies and Institutions Mentioned Oregon Health &...

BioCentury | Jun 04, 2019

Tools & Techniques

OHSU's Mitalipov proposes path forward for germline gene editing

...to conduct human germline gene editing research. In the perspective piece, Mitalipov and colleagues at Oregon Health &...
...receptor 5; MYBPC3 - myosin binding protein C cardiac; RAD51 - RAD51 homolog Mary Romeo, Staff Writer Oregon Health &...

BioCentury | Jun 04, 2019

Politics & Policy

House committee votes to reinstate human germline gene editing ban, calls for study of allowing mitochondrial replacement

...An amendment reinstating the rider was passed by voice vote. Shoukhrat Mitalipov and colleagues at Oregon Health &...

BioCentury | Mar 19, 2019

Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...there are models for what responsible studies could look like. In 2017, a group at Oregon Health &...
...Washington, D.C. National Academy of Sciences (NAS), Washington, D.C. New York University, New York, N.Y. Oregon Health &...

BioCentury | Dec 01, 2018

Politics, Policy & Law

China’s germline growing pain

...subsequent studies of germline gene editing in 2016 and 2017. Also in 2017, researchers at Oregon Health &...
...Medical Products Administration (NMPA), Beijing, China New York University School of Medicine, New York, N.Y. Oregon Health &...

BioCentury | Nov 26, 2018

Distillery Therapeutics

Cancer

...Nov. 1, 2018 doi:10.1084/jem.20180654 CONTACT: Amanda W. Lund, Oregon Health & Science University, Portland, Ore. email: lunda@ohsu.edu Claire Quang Oregon Health &...

BioCentury | Nov 06, 2018

Distillery Techniques

Assays and screens; biomarkers

...Tyner, J. et al. Nature ; published online Oct. 17, 2018 doi:10.1038/s41586-018-0623-z CONTACT: Brian Druker, Oregon Health &...
...Other) Zelboraf (Brand), RO5185426 (Compound #), RG7204 (Compound #), R7204 (Compound #), PLX4032 (Compound #), vemurafenib (Generic) Oregon Health &...

BioCentury | Nov 01, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

...Talin 1 (TLN1) Fruit fly studies suggest inhibiting TLN1 or TNS1 could help treat seizures Oregon Health &...

BioCentury | Oct 31, 2018

Distillery Techniques

Biomarkers

...12, 2018 doi:10.1126/sciadv.aat7828 CONTACT: Melissa H. Wong, Oregon Health & Science University, Portland, Ore. email: wongme@ohsu.edu Jaime De Leon Oregon Health &...

BioCentury | Oct 26, 2018

Regulation

Learning the limits of limited use

...of antibacterials for at least six months. Kevin Winthrop, a professor of infectious disease at Oregon Health &...
...tally against approval in the broader population. Kevin Winthrop, a professor of infectious disease at Oregon Health &...
...F2G Ltd., Eccles, U.K. Insmed Inc. (NASDAQ:INSM), Bridgewater, N.J. Loyola University Medical Center, Maywood, Ill. Oregon Health &...

BioCentury | Oct 25, 2018

Distillery Therapeutics

Neurology

...Oct. 16, 2018 doi:10.1073/pnas.1800830115 CONTACT: Marc R. Freeman, Oregon Health & Science University, Portland, Ore. email: freemmar@ohsu.edu Claire Quang Oregon Health &...

BioCentury | Oct 11, 2018

Translation in Brief

Public funding highlights: 3Q18

...Children's National Health System , Ontario Institute for Cancer Research (OICR), University of Chicago , Oregon Health &...

BioCentury | Aug 29, 2018

Distillery Therapeutics

Cancer

...online June 22, 2018 doi:10.1038/s41467-018-04465-5 CONTACT: Raymond Bergan, Oregon Health & Science University, Portland, Ore. email: bergan@ohsu.edu Chris Lieu Oregon Health &...

BioCentury | Aug 22, 2018

Translation in Brief

Confirming CRISPR

...and off-target edits. In a paper published in Nature last year, a team led by Oregon Health &...
...editing,” are needed to assess the possible consequences of base editing. Mary Romeo, Staff Writer Editas Medicine Inc. Oregon Health &...

BioCentury | Jul 19, 2018

Translation in Brief

Public Funding Highlights: 2Q18

...the New York Structural Biology Center , SLAC National Accelerator Laboratory at Stanford University and Oregon Health &...

BioCentury | May 24, 2018

Emerging Company Profile

Hitching a (Gene)Ride

...Metabolic Clinical status: Preclinical Founded: 2014 by Mark Kay, Adi Barzel, Leszek Lisowski University collaborators: Oregon Health &...

BioCentury | May 16, 2018

Politics & Policy

NIH to increase cryo-electron microscopy access

...California Institute of Technology, Purdue University, University of Utah and Yale University. Allison Johnson California Institute of Technology Oregon Health &...

BioCentury | Mar 30, 2018

Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

...an ongoing trial of ibudilast to treat methamphetamine use disorder that is being conducted at Oregon Health &...
...data Milestone: NA Elizabeth S. Eaton Ketas, ibudilast (AV411, MN-166, AV-411) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. National Institutes of Health Oregon Health &...

BioCentury | Mar 29, 2018

Clinical News

MediciNova sinks after meth dependence failure

...an ongoing trial of ibudilast to treat methamphetamine use disorder that is being conducted at Oregon Health &...
...Feb. 16) . Elizabeth S. Eaton Ketas, ibudilast (AV411, MN-166, AV-411) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. National Institutes of Health Oregon Health &...

BioCentury | Mar 01, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

...M. tuberculosis antigens including M. tuberculosis vapB47, rpfA, rpfD and Rv2626 could help prevent TB. Oregon Health &...

BioCentury | Feb 06, 2018

Distillery Therapeutics

Infectious disease

...Jan. 15, 2018 doi:10.1038/nm.4473 CONTACT: Louis Picker, Oregon Health & Science University (OHSU), Beaverton, Ore. email: pickerl@ohsu.edu Hongjiang Li Oregon Health &...

BioCentury | Jan 04, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...a Cas13b/adenosine deaminase RNA-specific B2 (ADARB2)-based RNA editor could help treat X-linked nephrogenic diabetes insipidus. Oregon Health &...

BioCentury | Jan 04, 2018

Distillery Techniques

Disease models

...Nov. 10, 2017 doi:10.1038/s41467-017-01631-z CONTACT: Jonah B. Sacha, Oregon Health & Science University, Beaverton, Ore. email: sacha@ohsu.edu Hongjiang Li Oregon Health &...

BioCentury | Dec 20, 2017

Distillery Techniques

Drug platforms

...Broad Institute of MIT and Harvard, Cambridge, Mass. email: zhang@broadinstitute.org Winnie Pong Broad Institute of MIT and Harvard Oregon Health &...

BioCentury | Nov 30, 2017

Company News

Ymir and Knight Cancer Institute partner to develop HCC biomarkers

...Ymir Genomics LLC (Cambridge, Mass.) and the Knight Cancer Institute at Oregon Health & Science University (Portland, Ore...
...financial terms. Oregon Health & Science University, Portland, Ore. Ymir Genomics LLC, Cambridge, Mass. Business: Cancer Jaime De Leon Oregon Health &...

BioCentury | Nov 17, 2017

Company News

Biological Dynamics and OHSU partner for early cancer detection

...diagnostics company Biological Dynamics Inc. (San Diego, Calif.) partnered with the Knight Cancer Institute at Oregon Health &...
...at Oregon Health & Science University (OHSU), Portland, Ore. Business: Cancer Shannon Lehnbeuter Biological Dynamics Inc. Knight Cancer Institute at Oregon Health &...

BioCentury | Nov 10, 2017

Product R&D

Blueprint gets the GIST

...first targeted therapies in cancer created by rational drug design. Druker is director of the Oregon Health &...
...York, N.Y. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Novartis Institutes for BioMedical Research, Cambridge, Mass. Oregon Health &...
...“Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. ” Nature (2010) Michael Leviten, Senior Writer BLU-285 Blueprint Bio Inc. Oregon Health &...

BioCentury | Nov 01, 2017

Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

...studies suggest inhibiting DDT could help treat progressive MS. VA Portland Health Care System ; Oregon Health &...

BioCentury | Oct 20, 2017

Company News

Vir unveils series of deals, additional funding

...$1 billion in milestones. Vir also announced partnerships with Stanford University , Harvard University , Oregon Health &...

BioCentury | Oct 19, 2017

Emerging Company Profile

Anti-bug big house

...by Robert Nelsen and ARCH Venture Partners University collaborators: Stanford University , Harvard University , Oregon Health &...

BioCentury | Oct 18, 2017

Company News

Vir unveils series of deals, additional funding

...$1 billion in milestones. Vir also announced partnerships with Stanford University , Harvard University , Oregon Health &...
...Cancer Research Center . Karen Tkach Tuzman VIS410 Alnylam Pharmaceuticals Inc. Biogen Inc. Fred Hutchinson Cancer Research Center Harvard University Humabs BioMed S.A. Oregon Health &...

BioCentury | Oct 13, 2017

Regulation

Seeking surrogates

...run by researchers from the University of Florida , the Children’s Hospital of Philadelphia , Oregon Health &...
...Path Institute, Tucson, Ariz. European Medicines Agency (EMA), London, U.K. Flagship Biosciences Inc., Westminster, Colo. Oregon Health &...

BioCentury | Sep 29, 2017

Preclinical News

Researchers use base editing to correct beta-thalassemia mutation

...techniques have produced a small number of mosaic embryos, a recent study by researchers at Oregon Health &...

BioCentury | Sep 14, 2017

Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

...could be used to correct hypertrophic cardiomyopathy-causing mutations in the MYBPC3 gene in human embryos. Oregon Health &...

BioCentury | Aug 09, 2017

Distillery Techniques

Drug platforms

...online Aug. 2, 2017 doi:10.1038/nature23305 CONTACT: Shoukhrat Mitalipov, Oregon Health & Science University, Portland, Ore. email: mitalipo@ohsu.edu Lauren Martz Oregon Health &...

BioCentury | Aug 03, 2017

Tools & Techniques

The other side of the Rubicon

...performed efficiently and without leading to the much-feared slew of off-target cuts, a team at Oregon Health &...
...Date Aug. 2, 2017 March 1, 2017 April 6, 2016 April 1, 2015 Primary institution Oregon Health &...
...Washington, D.C. National Institutes of Health (NIH), Bethesda, Md. New York University, New York, N.Y. Oregon Health &...

BioCentury | Aug 02, 2017

Preclinical News

U.S. researchers buck embryo editing guidelines

...the position against germline gene editing taken by NIH, a team led by scientists from Oregon Health &...

BioCentury | May 23, 2017

Regulation

Misalignment in autism

...autistic meeting participant named Michael. “Oftentimes it’s the way we ask the questions.” Christina Nicolaidis, Oregon Health &...
...developmental disabilities including autism. Nicolaidis is an associate professor of medicine and public health at Oregon Health &...
...Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Curemark LLC, Rye, N.Y. Indiana University, Indianapolis, Ind. Oregon Health &...

BioCentury | Jul 29, 2020

Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...a start-up around an RNA editing technology in the research lab of Gail Mandel at Oregon Health &...

BioCentury | Oct 06, 2016

Distillery Therapeutics

Therapeutics: Potassium channel Kv1.3 (KCNA3)

...Eil , R. et al. Nature; published online Sept. 14, 2016 doi:10.1038/nature19364 CONTACT: Robert Eil, Oregon Health &...

BioCentury | Aug 08, 2016

Emerging Company Profile

Interrogating immunity

...and physiologic, prognostic and genotypic data from exceptional responders. The company is also partnered with Oregon Health &...
...Inc., Redwood City, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. OncoResponse Inc., Seattle, Wash. Oregon Health &...
...Stocks, Kristine Swiderek, Steven Gillis University collaborators: University of Texas MD Anderson Cancer Center , Oregon Health &...

BioCentury | Jul 21, 2016

Translation in Brief

Survival of the modified

...strategy commonly used to clone cells in vitro has been co-opted by a group at Oregon Health &...

BioCentury | Jun 30, 2016

Distillery Techniques

Techniques: In vivo selection of genetically modified hepatocytes to improve efficacy of hepatocyte-targeting gene therapies

...S. et al. Sci. Trans. Med.; published online June 8, 2016 doi:10.1126/scitranslmed.aad8166 CONTACT: Markus Grompe, Oregon Health &...

BioCentury | Apr 21, 2016

Targets & Mechanisms

Structural SERT-ainty

...the central ligand binding site. Gouaux is a senior scientist at the Vollum Institute at Oregon Health &...
...Hughes Medical Institute (HHMI), Chevy Chase, Md. MabVax Therapeutics Holdings Inc. (OTCQB:MBVX), San Diego, Calif. Oregon Health &...
...twice In a study published in Nature , a team from the Vollum Institute at Oregon Health &...

BioCentury | Mar 03, 2016

Translation in Brief

Better AAV reception

...A group from Stanford University School of Medicine and Oregon Health & Science University (OHSU) has discovered a...

BioCentury | Feb 01, 2016

Company News

Oregon Health & Science University, OncoResponse deal

...rights to the antibodies generated under the deal. The partners declined to disclose financial terms. Oregon Health &...

BioCentury | Dec 15, 2015

Clinical News

Cancer Research UK, OHSU to study early detection

...Cancer Research UK (London, U.K.) partnered with the Knight Cancer Institute at Oregon Health & Science University to...

BioCentury | Dec 07, 2015

Company News

The Foundation for AIDS Research infectious news

...well as the Gladstone Institutes (San Francisco, Calif.), Blood Systems Research Institute (San Francisco, Calif.), Oregon Health &...

BioCentury | Dec 01, 2015

Clinical News

amfAR establishes HIV institute at UCSF

The Foundation for AIDS Research (amfAR) formed the amfAR Institute for HIV Cure Research at the University of California San Francisco with a five-year, $20 million grant. The funding is part of a $100 million...

BioCentury | Oct 01, 2015

Tools & Techniques

NCATS's extracellular revolution

...two years will be focused on validating the findings. Saugstad is an associate professor at Oregon Health &...
...NCATS), Bethesda, Md. National Institutes of Health (NIH), Bethesda, Md. Ohio State University, Columbus, Ohio Oregon Health &...
...NCATS $1,826,881 Clinical Utility of MicroRNAs as Diagnostic Biomarkers of Alzheimer's Disease Julie Anne Saugstad Oregon Health &...

BioCentury | Aug 13, 2015

Tools & Techniques

Helping Beethoven hear

...acetylcholine receptor α10 (CHRNA10) CHRNA9 and CHRNA10 activation January 2009 Acquired hearing loss Samuel Gubbels, Oregon Health &...

BioCentury | Jul 29, 2015

Clinical News

Loxo gains after patient responds in LOXO-101 trial

...Extra, July 10, 2013) . University of Colorado Cancer Center, the Knight Cancer Institute at Oregon Health &...

BioCentury | Jun 26, 2015

Financial News

OHSU's Knight Cancer Institute nets $1B

...The Knight Cancer Institute at Oregon Health & Science University said it raised $500 million, triggering a matching...

BioCentury | Jun 25, 2015

Distillery Therapeutics

Therapeutics: cAMP responsive element binding protein 1 (CREB1; CREB)

...F. et al. J. Med. Chem.; published online May 29, 2015 doi:10.1021/acs.jmedchem.5b00468 CONTACT: Xiangshu Xiao, Oregon Health &...

BioCentury | May 14, 2015

Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC)

...C. et al. Nat. Med.; published online May 4, 2015 doi: 10.1038/nm.3855 CONTACT: Charles Keller, Oregon Health &...

BioCentury | Feb 12, 2015

Product R&D

Re-enlisting Inlyta

...additional mutations are probably low. Michael Heinrich, professor of medicine and cell biology at the Oregon Health &...
...Helsinki, Finland National Institutes of Health (NIH), Bethesda, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oregon Health &...

BioCentury | Nov 13, 2014

Translation in Brief

Translational tidbits

...million Partnership for the development of low-cost chip and device for HCV testing Kineta Inc. Oregon Health &...

BioCentury | Nov 13, 2014

Cover Story

Boosting adjuvants

...vaccines. Nelson is one of the new award recipients and a senior molecular virologist at Oregon Health &...
...and T cells, resulting in powerful adaptive immune responses," he said. Nelson's team at the Oregon Health &...
...Bethesda, Md. National Institutes of Health , Bethesda, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oregon Health &...

BioCentury | Oct 20, 2014

Company News

Aptose Biosciences, Oregon Health & Science University, LLS cancer news

...combinations of drugs (see BioCentury, Sept. 23, 2013). Aptose Biosciences Inc. (TSX:APS; Pink:APSCF), Toronto, Ontario Oregon Health &...

BioCentury | Oct 16, 2014

Translation in Brief

Translational tidbits

...at Mount Sinai; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; NIH; Oregon Health &...

BioCentury | Oct 13, 2014

Company News

Novo Nordisk endocrine/metabolic news

...will join Novo Nordisk to head the unit. Grove was a senior scientist at the Oregon Health &...

BioCentury | Oct 01, 2014

Politics & Policy

NIAID funds development of new vaccine adjuvants

...the Corixa Corp. (Seattle, Wash.) unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Duke University (Durham, N.C.); Oregon Health &...

BioCentury | Sep 29, 2014

Company News

Broad Institute, Harvard Medical School, Icahn School of Medicine at Mount Sinai, NIH, Oregon Health and Science University (OHSU), University of California bio

NIH awarded more than $64 million to five research institutions to create the Library of Integrated Network-based Cellular Signatures (LINCS), a database of human cellular responses. The LINCS program aims to catalog and analyze cellular...

BioCentury | Sep 15, 2014

Product Development

Learning from Gleevec

...achieve sustained remissions from other targeted cancer therapies, according to Brian Druker, director of the Oregon Health &...
...Biogen Idec Inc. and BIO. Companies and Institutions Mentioned Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oregon Health &...

BioCentury | Aug 11, 2014

Clinical News

Sovaldi sofosbuvir regulatory update

Oregon’s Pharmacy and Therapeutics Committee proposed guidelines that would restrict access to Gilead’s HCV drug Sovaldi sofosbuvir in the state’s Medicaid program. The guidelines would allow Sovaldi only for patients with late stage liver damage,...

BioCentury | Aug 07, 2014

Distillery Techniques

Technology: Disease models

...unavailable Ma, H. et al. Nature; published online July 2, 2014; doi:10.1038/nature13551 Contact: Shoukhrat Mitalipov, Oregon Health &...

BioCentury | Aug 05, 2014

Politics & Policy

Oregon Medicaid looks to restrict Sovaldi access

Oregon's Pharmacy and Therapeutics Committee proposed guidelines that would restrict HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) in the state's Medicaid program. The guidelines would allow access only to patients with late stage...

BioCentury | Jun 20, 2014

Politics & Policy

21st Century Cures to host roundtable

The House Energy and Commerce Committee's 21st Century Cures initiative will host a roundtable June 24 to discuss how technology can accelerate discovery, development and delivery of new cures and treatments. Participants include Jeffrey Shuren,...

BioCentury | May 08, 2014

Distillery Therapeutics

Indication: Cancer

...al. Proc. Natl. Acad. Sci. USA; published online April 14, 2014; doi:10.1073/pnas.1403608111 Contact: Charles Keller, Oregon Health &...

BioCentury | Apr 28, 2014

Company News

Response Genetics, Oregon Health & Science University sales and marketing update

...details, and the university could not be reached. Response Genetics Inc. (NASDAQ:RGDX), Los Angeles, Calif. Oregon Health &...

BioCentury | Apr 24, 2014

Cover Story

CRISPR in the liver

...off-target editing. Data were published in Nature Biotechnology . The team also included researchers from Oregon Health &...
...of Technology , Cambridge, Mass. McGovern Institute for Brain Research at MIT , Cambridge, Mass. Oregon Health &...

BioCentury | Feb 20, 2014

Cover Story

Europe's upwelling

...Partnership Against Cancer; Heart and Stroke Foundation C$16 ($15.3) Illumina Inc. (NASDAQ:ILMN); Intel Corp. (NASDAQ:INTC) Oregon Health &...

BioCentury | Jan 30, 2014

Targets & Mechanisms

PTSD: rewriting fearful memories

...fear and the recalled memory." K. Matthew Lattal, an associate professor of behavioral neuroscience at Oregon Health &...
...Massachusetts Institute of Technology , Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Oregon Health &...

BioCentury | Jan 27, 2014

Emerging Company Profile

Salarius: Kicking LSD

...Sunil Sharma and David Bearss University collaborators: University of Utah, Methodist Hospital Research Institute and Oregon Health &...

BioCentury | Dec 19, 2013

Distillery Therapeutics

Indication: Cancer

...with crizotinib-resistant tumors. The trial is being designed by GlaxoSmithKline plc in partnership with the Oregon Health &...
...Proc. Natl. Acad. Sci. USA; published online Nov. 11, 2013; doi:10.1073/pnas.1319583110 Contact: Brian J. Druker, Oregon Health &...

BioCentury | Nov 14, 2013

Distillery Techniques

Technology: Disease models

...unavailable Wang, H. et al. Nature; published online Oct. 13, 2013; doi:10.1038/nature12648 Contact: Eric Gouaux, Oregon Health &...

BioCentury | Oct 10, 2013

Translation in Brief

Translational tidbits

...gene-based therapies in the U.K. and improving supply chains Illumina Inc. (NASDAQ:ILMN); Intel Corp. (NASDAQ:INTC) Oregon Health &...

BioCentury | Oct 10, 2013

Distillery Techniques

Technology: Drug platforms

...unavailable Penmatsa, A. et al. Nature; published online Sept. 15, 2013; doi:10.1038/nature12533 Contact: Eric Gouaux, Oregon Health &...

BioCentury | Oct 10, 2013

Distillery Therapeutics

Indication: Infectious disease

...macaques with established SIV infection. SciBX 6(39); doi:10.1038/scibx.2013.1099 Published online Oct. 10, 2013 Patented by Oregon Health &...
...Hansen, S.G. et al. Nature; published online Sept. 11, 2013; doi:10.1038/nature12519 Contact: Louis J. Picker, Oregon Health &...

BioCentury | Sep 24, 2013

Politics & Policy

Nike co-founder pledges $500M for cancer research

...$500 million to a $1 billion cancer research initiative at the Knight Cancer Institute at Oregon Health &...

BioCentury | Sep 23, 2013

Company News

Oregon Health & Science University, LLS cancer news

...sequencing expertise and Intel Corp. (NASDAQ:INTC, Santa Clara, Calif.) will be responsible for computational analysis. Oregon Health &...

BioCentury | Sep 19, 2013

Distillery Therapeutics

Indication: Neurology

...Garg, S.K. et al. J. Neurosci.; published online Aug. 21, 2013; doi:10.1523/JNEUROSCI.1854-13.2013 Contact: Gail Mandel, Oregon Health &...

BioCentury | Sep 02, 2013

Strategy

Back to School 2013: Facing reality

...from Novartis AG as an example. Among the authors was Brian Drucker, a physician-scientist at Oregon Health &...
...Institute for Health and Care Excellence (NICE), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oregon Health &...

BioCentury | Jul 01, 2013

Company News

Latitude Pharmaceuticals, Xeris, Juvenile Diabetes Research Foundation International (JDRF) deal

...two years of milestone-based funding, with clinical testing slated to begin in 1Q14 at the Oregon Health &...

BioCentury | Jun 24, 2013

Clinical News

InFuse Bone Graft: Postmarketing study data

...with InFuse (see BioCentury, Aug. 8, 2011). Yale subsequently commissioned a panel of researchers from Oregon Health &...
...with InFuse (see BioCentury, Aug. 8, 2011). Yale subsequently commissioned a panel of researchers from Oregon Health &...

BioCentury | Jun 19, 2013

Clinical News

Independent reviews of Medtronic's InFuse published

...data from 13 randomized controlled trials sponsored by Medtronic and 31 cohort studies, researchers at Oregon Health &...

BioCentury | Jun 06, 2013

Distillery Techniques

Technology: Markers

...al. N. Engl. J. Med.; published online May 9, 2013; doi:10.1056/NEJMoa1214514 Contact: Jeffrey W. Tyner, Oregon Health &...

BioCentury | May 30, 2013

Distillery Techniques

Technology: Approach

...licensing Tachibana, M. et al. Cell; published online May 15, 2013; doi:10.1016/j.cell.2013.05.006 Contact: Shoukhrat Mitalipov, Oregon Health &...